Compare · IVVD vs REGN
IVVD vs REGN
Side-by-side comparison of Invivyd Inc. (IVVD) and Regeneron Pharmaceuticals Inc. (REGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IVVD focuses on Biotechnology: Biological Products (No Diagnostic Substances), while REGN focuses on Biotechnology: Pharmaceutical Preparations.
- REGN is the larger of the two at $98.52B, about 616.8x IVVD ($159.7M).
- Over the past year, IVVD is down 81.1% and REGN is up 35.3% - REGN leads by 116.4 points.
- REGN has been more active in the news (18 items in the past 4 weeks vs 4 for IVVD).
- REGN has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- Invivyd Inc.
- Regeneron Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $159.7M
- $98.52B
- 1M return
- -13.22%
- +20.40%
- 1Y return
- -81.08%
- +35.34%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 1991
- News (4w)
- 4
- 18
- Recent ratings
- 7
- 25
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Latest IVVD
- SEC Form 10-Q filed by Invivyd Inc.
- Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
- Invivyd to Participate in Upcoming September Investor Conferences
Latest REGN
- POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
- CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
- SVP Controller Pitofsky Jason exercised 3,883 shares at a strike of $640.66 and sold $3,827,159 worth of shares (4,062 units at $942.19) (SEC Form 4)
- Co-Chief Scientific Officer Murphy Andrew J gifted 1,054 shares, decreasing direct ownership by 2% to 46,779 units (SEC Form 4)
- SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.
- Director Zoghbi Huda Y exercised 7,439 shares at a strike of $380.95 and sold $7,219,274 worth of shares (7,439 units at $970.46) (SEC Form 4)
- Director Sing George L exercised 15,269 shares at a strike of $378.77 and sold $20,376,358 worth of shares (21,129 units at $964.38), decreasing direct ownership by 19% to 25,147 units (SEC Form 4)
- Director Poon Christine A exercised 7,830 shares at a strike of $376.69 and sold $7,587,958 worth of shares (7,830 units at $969.09) (SEC Form 4)
- EVP Finance CFO Fenimore Christopher R. exercised 6,000 shares at a strike of $381.92, covered exercise/tax liability with 4,243 shares and gifted 15 shares, increasing direct ownership by 9% to 21,726 units (SEC Form 4)
- EVP General Counsel and Secret Larosa Joseph J exercised 12,283 shares at a strike of $381.92, covered exercise/tax liability with 8,686 shares and sold $4,311,890 worth of shares (4,466 units at $965.49), decreasing direct ownership by 2% to 38,906 units (SEC Form 4)